Now showing items 1-10 of 18
Radiation therapy combined with hormone treatment for primary prostate cancer. Effects of radiation dose escalations and assessment of side effects
(The University of Bergen, 2009-05-06)
Adjuvant treatment: the contribution of expression microarrays
(BioMed Central, 2007-12-20)
CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
(Public Library of Science, 2008-08-26)
Background: Chemoresistance is the main obstacle to cure in most malignant diseases. Anthracyclines are among the main drugs used for breast cancer therapy and in many other malignant conditions. Single parameter analysis ...
MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk
(Public Library of Science, 2012-04-30)
The MDM2 proto-oncogene plays a key role in central cellular processes like growth control and apoptosis, and the gene locus is frequently amplified in sarcomas. Two polymorphisms located in the MDM2 promoter P2 have been ...
Genetic biomarkers as prognostic and predictive factors in metastatic malignant melanoma
(The University of Bergen, 2010-10-26)
Malignant melanoma is one of the most chemoresistant malignancies in man. Although effort is put into developing new drugs to treat metastatic melanoma, still dacarbazine, an alkylating agent approved in 1975 for therapeutic ...
Resistance to Chemotherapy in Breast Cancer: Potential role of p21B, p27 and the p53 apoptotic pathway
(The University of Bergen, 2009-03-13)
AIDS-related primary central nervous system lymphoma: a Norwegian national survey 1989–2003
(BioMed Central, 2008-08-06)
Background: Primary central nervous system lymphoma (PCNSL) is a frequent complication in acquired immunodeficiency syndrome (AIDS). The objective of this survey was to investigate incidence, clinical features, radiological ...
DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response
(BioMed Central, 2010-03-25)
Background: Breast cancer is the most frequent cancer in women and consists of a heterogeneous collection of diseases with distinct histopathological, genetic and epigenetic characteristics. In this study, we aimed to ...
Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
(BioMed Central, 2012-10-05)
<p>Background: While BRCA mutation carriers possess a 20-40% lifetime risk of developing ovarian cancer, knowledge about genetic modifying factors influencing the phenotypic expression remains obscure. We explored the ...